Abelacimab

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAbelacimab
Drug Alias NameMAA-868NOV-12
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCoagulation factor XI inhibitorsFactor XIa inhibitors
TargetsCoagulation factor XI
Therapy Area/IndicationsVenous ThrombosisVenous ThromboembolismThromboembolism +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[41] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesAnthos Therapeutics IncNovartis Pharma AgChina Novartis Institutes For Biomedical Research Co Ltd +[4] 
Inactive CompaniesIqvia Rds (Shanghai) Co Ltd
Active IndicationsThromboembolismEmbolismAtrial Fibrillation +[4] 
Inactive IndicationsVenous ThrombosisVenous ThromboembolismPulmonary Embolism +[4] 

Other Information

ATC CodeN/A
Related LinksN/A